148 related articles for article (PubMed ID: 37017812)
61. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF.
Wenzel C; Bartsch R; Hussian D; Pluschnig U; Altorjai G; Zielinski CC; Lang A; Haid A; Jakesz R; Gnant M; Steger GG
Breast Cancer Res Treat; 2007 Jul; 104(1):109-14. PubMed ID: 17061042
[TBL] [Abstract][Full Text] [Related]
62. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome.
Arpino G; Bardou VJ; Clark GM; Elledge RM
Breast Cancer Res; 2004; 6(3):R149-56. PubMed ID: 15084238
[TBL] [Abstract][Full Text] [Related]
63. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
64. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
65. Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit.
de Nonneville A; Jauffret C; Gonçalves A; Classe JM; Cohen M; Reyal F; Mazouni C; Chauvet MP; Chopin N; Colombo PE; Jouve E; Darai E; Rouzier R; Coutant C; Gimbergues P; Azuar AS; de Lara CT; Lambaudie E; Houvenaeghel G
Breast Cancer Res Treat; 2019 Jun; 175(2):379-387. PubMed ID: 30759288
[TBL] [Abstract][Full Text] [Related]
66. Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes.
Kaur M; Patterson A; Molina-Vega J; Rothschild H; Clelland E; Ewing CA; Mujir F; Esserman LJ; Olopade OI; Mukhtar RA
Cancer Epidemiol Biomarkers Prev; 2023 Aug; 32(8):1107-1113. PubMed ID: 37257200
[TBL] [Abstract][Full Text] [Related]
67. The 70-gene signature test as a prognostic and predictive biomarker in patients with invasive lobular breast cancer.
Jenkins JA; Marmor S; Hui JYC; Beckwith H; Blaes AH; Potter D; Tuttle TM
Breast Cancer Res Treat; 2022 Jan; 191(2):401-407. PubMed ID: 34716509
[TBL] [Abstract][Full Text] [Related]
68. Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma.
Nasrazadani A; Li Y; Fang Y; Shah O; Atkinson JM; Lee JS; McAuliffe PF; Bhargava R; Tseng G; Lee AV; Lucas PC; Oesterreich S; Wolmark N
Br J Cancer; 2023 Apr; 128(6):1030-1039. PubMed ID: 36604587
[TBL] [Abstract][Full Text] [Related]
69. [Invasive lobular carcinoma of basal-like subtype of breast: a clinicopathologic analysis].
Zhang LY; Gao LX; Liu G; Yang GZ; Cheng J; Ding HY
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):599-603. PubMed ID: 24314245
[TBL] [Abstract][Full Text] [Related]
70. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
[TBL] [Abstract][Full Text] [Related]
71. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.
Delpech Y; Coutant C; Hsu L; Barranger E; Iwamoto T; Barcenas CH; Hortobagyi GN; Rouzier R; Esteva FJ; Pusztai L
Br J Cancer; 2013 Feb; 108(2):285-91. PubMed ID: 23299541
[TBL] [Abstract][Full Text] [Related]
72. Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer.
Pramod N; Nigam A; Basree M; Mawalkar R; Mehra S; Shinde N; Tozbikian G; Williams N; Majumder S; Ramaswamy B
Oncologist; 2021 Jun; 26(6):e943-e953. PubMed ID: 33641217
[TBL] [Abstract][Full Text] [Related]
73. Clinical outcomes and prognostic factors in triple-negative invasive lobular carcinoma of the breast.
Joshi U; Budhathoki P; Gaire S; Yadav SK; Shah A; Adhikari A; Choong G; Couzi R; Giridhar KV; Leon-Ferre RA; Boughey JC; Hieken TJ; Mutter R; Ruddy KJ; Haddad TC; Goetz MP; Couch FJ; Yadav S
Breast Cancer Res Treat; 2023 Jul; 200(2):217-224. PubMed ID: 37210429
[TBL] [Abstract][Full Text] [Related]
74. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
Khabaz MN
Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
[TBL] [Abstract][Full Text] [Related]
75. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
76. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes.
Rakha EA; El-Sayed ME; Powe DG; Green AR; Habashy H; Grainge MJ; Robertson JF; Blamey R; Gee J; Nicholson RI; Lee AH; Ellis IO
Eur J Cancer; 2008 Jan; 44(1):73-83. PubMed ID: 18035533
[TBL] [Abstract][Full Text] [Related]
77. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.
Mouabbi JA; Hassan A; Lim B; Hortobagyi GN; Tripathy D; Layman RM
Breast Cancer Res Treat; 2022 Jun; 193(2):253-264. PubMed ID: 35347549
[TBL] [Abstract][Full Text] [Related]
78. The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients.
Korhonen T; Kuukasjärvi T; Huhtala H; Alarmo EL; Holli K; Kallioniemi A; Pylkkänen L
Breast; 2013 Dec; 22(6):1119-24. PubMed ID: 23863867
[TBL] [Abstract][Full Text] [Related]
79. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
[TBL] [Abstract][Full Text] [Related]
80. P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer.
Turashvili G; McKinney SE; Goktepe O; Leung SC; Huntsman DG; Gelmon KA; Los G; Rejto PA; Aparicio SA
Mod Pathol; 2011 Jan; 24(1):64-81. PubMed ID: 20852590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
